Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS® is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals.
NiSource Divests 19.9% Stake In Indiana-Based Unit To Blackstone For $2.15B
NiSource Inc (NYSE: NI) has inked a pact with Blackstone Inc. (NYSE: BX) to
